Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 1898
interventional 1685
Observational 193
Registry 20

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 964
Biological 123
Biological|Drug 74
Drug|Other 63
Drug|Procedure 61
Biological|Drug|Procedure 44
Drug|placebo 33
Biological|Drug|Procedure|Radiation 31
Procedure 31
Drug|Procedure|Radiation 25
Other 24
Biological|Drug|Other 20
Drug|Other|Procedure|Radiation 17
Device 13
Biological|Other 12
Drug|Other|Procedure 11
Behavioral 10
Drug|Radiation 10
Biological|Drug|Other|Procedure 9
Biological|Drug|Radiation 9
Biological|Drug|Other|Procedure|Radiation 8
Biological|Procedure 6
Combination Product 6
Drug|Genetic 6
Dietary Supplement|Drug 4
Drug|Genetic|Other|Procedure 4
Other|Procedure 4
Behavioral|Drug 3
Biological|Drug|placebo 3
Biological|placebo 3
Device|Drug|Procedure 3
Behavioral|Drug|Procedure 2
Behavioral|Other 2
Biological|Genetic|Other 2
Biological|Radiation 2
Device|Drug|Other 2
Device|Other 2
Device|Radiation 2
Diagnostic Test 2
Dietary Supplement 2
Drug|Other|Radiation 2
Drug|placebo|Procedure 2
Genetic 2
Behavioral|Biological|Drug 1
Behavioral|Diagnostic Test|Other 1
Behavioral|Dietary Supplement|Other|Procedure 1
Behavioral|Drug|placebo 1
Biological|Device|Drug|Procedure|Radiation 1
Biological|Device|Drug|Radiation 1
Biological|Dietary Supplement|Drug|placebo 1
Biological|Drug|Genetic 1
Biological|Drug|Genetic|Other|Procedure 1
Biological|Drug|Genetic|Procedure|Radiation 1
Biological|Drug|Other|placebo 1
Biological|Other|Procedure 1
Combination Product|Drug 1
Device|Drug 1
Device|Other|Procedure 1
Device|Procedure 1
Diagnostic Test|Drug|Other 1
Dietary Supplement|Other|placebo 1
Dietary Supplement|placebo 1
Drug|Genetic|Other 1
Drug|Genetic|Procedure 1
Drug|Genetic|Procedure|Radiation 1
Drug|Other|placebo 1
Drug|Other|placebo|Procedure 1
Genetic|Radiation 1
Other|Radiation 1
Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 954
NA 65
China 64
France 41
Italy 31
United States|Canada 30
Germany 29
Canada 28
Spain 26
Japan 24
United Kingdom 23
Denmark 13
Korea, Republic of 13
Switzerland 9
Netherlands 8
United States|Italy 8
Australia 7
United States|Germany|Italy 6
Israel 5
Taiwan 5
United States|Australia 5
Austria 4
Poland 4
United States|Puerto Rico 4
Austria|Germany 3
Belgium 3
Belgium|France 3
Greece 3
India 3
Norway 3
Singapore 3
United States|France 3
United States|Israel 3
Austria|Czech Republic 2
Brazil 2
China|Taiwan 2
Denmark|Norway|Sweden 2
Finland 2
Hong Kong|Korea, Republic of|Singapore|Taiwan 2
Iceland 2
Ireland 2
Mexico 2
Russian Federation 2
Sweden 2
United States|Australia|Canada 2
United States|Australia|France 2
United States|Austria|Belgium|Canada|France|Germany|Ireland|Israel|Italy|Netherlands|Spain|Sweden|United Kingdom 2
United States|Denmark 2
United States|Denmark|Germany 2
United States|France|Spain 2
United States|Korea, Republic of 2
United States|United Kingdom 2
Argentina|Australia|United States|Canada|Czech Republic|France|Israel|Netherlands|Poland|Portugal|Russian Federation|Singapore|South Africa|Spain|United Kingdom|Austria|Belgium 1
Australia|Austria|Belarus|Belgium|Czech Republic|Denmark|France|Georgia|Germany|Greece|Ireland|Israel|Italy|Netherlands|Poland|Russian Federation|Spain|Sweden|Switzerland|Turkey|Ukraine|United Kingdom 1
Australia|Austria|Belgium|France|Germany|Greece|Ireland|Israel|Italy|Poland|Spain|Sweden|Switzerland|Ukraine|United Kingdom 1
Australia|Austria|Ireland|Spain|United Kingdom 1
Australia|Belgium|Canada|Czechia|Denmark|France|Germany|Greece|Italy|Netherlands|Russian Federation|Spain|Sweden|Switzerland|United Kingdom 1
Australia|Belgium|Czechia|Denmark|France|Greece|Italy|Netherlands|Norway|Poland|Spain|Switzerland|Turkey 1
Australia|Belgium|France|Italy|Korea, Republic of|Poland|Spain 1
Australia|China|Korea, Republic of 1
Australia|Denmark|Norway 1
Australia|France|Germany|Hungary|Korea, Republic of|Poland|Singapore|United Kingdom 1
Australia|France|Spain|United Kingdom 1
Austria|Belgium|Denmark|Estonia|Finland|France|Germany|Greece|Ireland|Italy|Netherlands|Norway|Poland|Portugal|Slovakia|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
Austria|Belgium|France|Germany|Greece|Luxembourg|Portugal|Spain 1
Austria|Czech Republic|Denmark|Germany|Greece|Sweden|Turkey|United Kingdom 1
Austria|Czechia|Denmark|Germany|Italy|Poland 1
Austria|Czechia|Germany 1
Austria|France|Germany|Greece|Italy|Netherlands|Spain|United Kingdom 1
Austria|France|Germany|Italy 1
Belarus 1
Belgium|Canada|Czech Republic|Finland|France|Germany|United States|Greece|Israel|Slovakia|Switzerland|Turkey|United Kingdom 1
Belgium|Czechia|Denmark|Germany|Greece|Italy|Netherlands|Serbia|Spain|Turkey 1
Belgium|Estonia|Lithuania|Sweden 1
Belgium|Finland|France|Germany|Israel|Netherlands|Norway|Poland|Portugal|Sweden|Turkey 1
Belgium|France|Germany 1
Belgium|France|Greece|Italy|Spain 1
Belgium|France|Netherlands 1
Belgium|France|Switzerland 1
Belgium|Israel|Spain 1
Bulgaria|Croatia|Czechia|France|Germany|Hungary|India|Italy|Philippines|Poland|Portugal|Serbia|Slovakia|South Africa|United Kingdom 1
Canada|United States 1
China|Hong Kong|Korea, Republic of|Malaysia|Taiwan 1
Czech Republic|United Kingdom 1
Czechia|Denmark|France|Germany|Netherlands|Norway|Poland|Spain|Sweden 1
Czechia|Germany|Greece|Italy|Spain|Turkey 1
Czechia|Greece|Ireland|Italy 1
Czechia|Poland 1
Czechia|United States|Bulgaria|France|Germany|Greece|Japan|Netherlands|Romania|Russian Federation|Spain|Sweden|Turkey 1
Denmark|Finland|Iceland|Norway|Sweden 1
Denmark|Finland|Lithuania|Norway|Sweden 1
Denmark|Germany|Ireland|United Kingdom 1
Finland|Lithuania|Norway|Sweden 1
Finland|Sweden 1
France|Germany 1
France|Germany|Italy|Spain 1
France|Italy 1
France|Spain 1
France|United Kingdom 1
France|United States|Belgium|Canada|Korea, Republic of|New Zealand|Russian Federation 1
Germany|Greece 1
Germany|Israel|Italy 1
Germany|Italy 1
Germany|Italy|Spain|Sweden 1
Germany|Netherlands|United Kingdom 1
Greece|Italy|Netherlands 1
Greece|Italy|Turkey 1
Greece|United States|Australia|Austria|Belgium|Canada|Czechia|Germany|Hungary|Ireland|Israel|Italy|Poland|Puerto Rico|Romania|Russian Federation|Spain|Switzerland|Turkey|United Kingdom 1
Greece|United States|Turkey|Austria|Canada|Denmark|Finland|France|Germany|Ireland|Israel|Italy|Japan|Netherlands|Norway|Poland|Portugal|Puerto Rico|Russian Federation|Spain|Sweden|United Kingdom 1
Hong Kong|Japan|Korea, Republic of|Singapore|Taiwan 1
Hong Kong|Korea, Republic of|Singapore 1
India|Korea, Republic of|Singapore 1
Iraq 1
Ireland|United Kingdom 1
Israel|Italy|Poland|South Africa|United Kingdom 1
Israel|Italy|United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Colombia|Czechia|Denmark|France|Germany|Greece|Hungary|Japan|Korea, Republic of|Mexico|Netherlands|Norway|Poland|Portugal|Singapore|South Africa|Spain|Sweden|Switzerland|Taiwan|Thailand|Turkey|Ukraine|United Kingdom 1
Italy|Japan|United States|Australia|France|Greece 1
Italy|Netherlands 1
Italy|Switzerland 1
Japan|United States|Argentina|Australia|Belgium|Brazil|Canada|Czechia|Denmark|France|Germany|Greece|Hungary|Israel|Italy|Mexico|Netherlands|Norway|Poland|Russian Federation|Spain|Sweden|Turkey|United Kingdom 1
Japan|United States|Australia|Brazil|Canada|Czechia|France|Greece|Israel|Italy|Korea, Republic of|Poland|Russian Federation|Spain|Sweden|Taiwan|Ukraine|United Kingdom 1
Netherlands|United Kingdom 1
Poland|Portugal|Romania|United States|Argentina|Australia|Belgium|Brazil|Bulgaria|Croatia|Czechia|Georgia|Germany|Greece|Hungary|Japan|Korea, Republic of|North Macedonia|Russian Federation|Serbia|Spain|Turkey|Ukraine|United Kingdom 1
Poland|Serbia|France|Germany|Greece|Hungary|Lithuania|Spain|Turkey|United Kingdom 1
Russian Federation|Ukraine 1
Saudi Arabia 1
Slovakia|Spain|Sweden|United Kingdom|Serbia|Australia|Austria|Belgium|Czechia|France|Germany|Greece|Hungary|Israel|Italy|Korea, Republic of|New Zealand|Poland|Russian Federation 1
Spain|France|Germany|Italy|Netherlands|Sweden|United Kingdom 1
Sweden|Denmark|Norway 1
Tunisia 1
Turkey 1
United States|Argentina 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|China|Czechia|Denmark|Egypt|Finland|France|Germany|Greece|Hong Kong|Israel|Italy|Japan|Korea, Republic of|Lebanon|Mexico|Netherlands|Norway|Poland|Russian Federation|Singapore|South Africa|Spain|Sweden|Taiwan|Thailand|Turkey|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Bulgaria|Canada|China|Czechia|Korea, Republic of|France|Germany|Greece|Hungary|Israel|Italy|Japan|Taiwan|Mexico|Netherlands|New Zealand|Poland|Romania|Russian Federation|Singapore|Spain|Switzerland|Turkey|Ukraine|United Kingdom 1
United States|Argentina|Mexico 1
United States|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|Czechia|France|Germany|Greece|Hungary|Israel|Italy|Japan|Korea, Republic of|New Zealand|Poland|Romania|Russian Federation|Singapore|Slovakia|Spain|Taiwan|Thailand|Ukraine|United Kingdom 1
United States|Australia|Austria|Belgium|Bulgaria|Canada|Czechia|France|Germany|Greece|Hungary|India|Israel|Italy|Poland|Romania|Russian Federation|Serbia|Spain|Ukraine|United Kingdom 1
United States|Australia|Austria|Belgium|Bulgaria|Canada|Czechia|France|Greece|Hungary|Japan|Korea, Republic of|Poland|Romania|Russian Federation|Spain|Taiwan|Turkey|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|China|France|Germany|Greece|Ireland|Italy|Korea, Republic of|New Zealand|Portugal|Spain|Sweden|Switzerland|Taiwan|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|Czechia|Denmark|France|Germany|Greece|Hungary|Ireland|Israel|Italy|Japan|Poland|Puerto Rico|Romania|Spain|Switzerland|Turkey|United Kingdom 1
United States|Australia|Austria|Belgium|Czechia|France|Germany|Greece|Ireland|Italy|Korea, Republic of|Netherlands|New Zealand|Poland|Portugal|Puerto Rico|Spain|Taiwan|United Kingdom 1
United States|Australia|Austria|Bulgaria|Canada|Czechia|France|Germany|Greece|Hong Kong|Hungary|Ireland|Italy|Japan|Korea, Republic of|Lithuania|Malaysia|New Zealand|Poland|Portugal|Russian Federation|Singapore|Slovakia|Spain|Switzerland|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Australia|Belgium|Brazil|Canada|Czechia|France|Germany|Greece|Hungary|Italy|Korea, Republic of|Lebanon|Netherlands|Norway|Poland|Portugal|Russian Federation|Spain|Sweden|Thailand|Turkey 1
United States|Australia|Belgium|Bulgaria|Canada|Germany|Hungary|Ireland|Israel|Italy|Poland|Russian Federation|Spain|Switzerland|Ukraine|United Kingdom 1
United States|Australia|Belgium|Canada|Czechia|Denmark|Finland|France|Germany|Greece|Hungary|Italy|Japan|New Zealand|Norway|Poland|Romania|Spain|Sweden|United Kingdom 1
United States|Australia|Belgium|Canada|Czechia|Denmark|France|Germany|Greece|Hungary|Italy|Japan|Korea, Republic of|New Zealand|Norway|Poland|Portugal|Russian Federation|Slovakia|Spain|Sweden|Taiwan|Turkey|United Kingdom 1
United States|Australia|Belgium|Canada|Czechia|Denmark|France|Germany|Greece|Israel|Italy|Netherlands|Norway|Russian Federation|Spain|Sweden|Turkey|United Kingdom 1
United States|Australia|Belgium|Canada|Czechia|Denmark|France|Germany|Greece|Italy|Netherlands|Russian Federation|Spain|Sweden|Switzerland|United Kingdom 1
United States|Australia|Belgium|Canada|Denmark|France|Germany|Greece|Israel|Japan|Korea, Republic of|Netherlands|Poland|Russian Federation|Spain|Sweden|Taiwan|United Kingdom 1
United States|Australia|Belgium|Canada|Netherlands|Spain 1
United States|Australia|Belgium|China|Czechia|Denmark|France|Germany|Greece|Italy|Japan|Lithuania|Mexico|New Zealand|Poland|Portugal|Russian Federation|Spain|Sweden|Taiwan|Turkey 1
United States|Australia|Belgium|Denmark|France|Germany|Israel|Italy|Japan|Korea, Republic of|Netherlands|Poland|Spain|Sweden|United Kingdom 1
United States|Australia|Belgium|France|Germany|Greece|Israel|Korea, Republic of|Spain|Sweden|United Kingdom 1
United States|Australia|Belgium|France|Spain 1
United States|Australia|Belgium|Japan|Switzerland 1
United States|Australia|Brazil|Canada|Czechia|France|Greece|Hungary|Italy|Japan|Korea, Republic of|New Zealand|Russian Federation|Spain|Turkey|United Kingdom 1
United States|Australia|Brazil|Canada|Czechia|France|Greece|Hungary|Italy|Spain 1
United States|Australia|Brazil|Czechia|Germany|Hungary|Korea, Republic of|Mexico|Netherlands|Poland|Russian Federation|Spain|Sweden|Turkey|Ukraine 1
United States|Australia|Canada|China|Czechia|France|Germany|Greece|Israel|Italy|Japan|Korea, Republic of|Russian Federation|Singapore|Spain|Sweden|Turkey|United Kingdom 1
United States|Australia|Canada|Czechia|France|Germany|Israel|Netherlands|Russian Federation|Turkey|United Kingdom 1
United States|Australia|Canada|Denmark|France|Germany 1
United States|Australia|Canada|France|Germany|Greece|Italy|Japan|Netherlands|Poland|Spain 1
United States|Australia|Canada|France|Germany|Italy|Korea, Republic of|Spain 1
United States|Australia|Canada|France|Germany|Italy|Spain|United Kingdom 1
United States|Australia|Canada|France|Germany|Netherlands|Turkey 1
United States|Australia|Canada|Germany|Italy|Spain 1
United States|Australia|Canada|Germany|Japan 1
United States|Australia|Canada|India 1
United States|Australia|Canada|Ireland|Taiwan 1
United States|Australia|Canada|Netherlands|Spain|Sweden 1
United States|Australia|France|Germany|Italy|Japan|Spain 1
United States|Australia|France|India|Israel|Korea, Republic of|Poland|Romania|Russian Federation|Singapore|Spain 1
United States|Australia|France|Israel|Japan|Spain|Taiwan 1
United States|Australia|France|Poland 1
United States|Australia|France|Spain 1
United States|Australia|France|Spain|United Kingdom 1
United States|Australia|Germany 1
United States|Australia|Germany|Italy|Singapore 1
United States|Australia|Germany|Japan|Netherlands 1
United States|Australia|Germany|Singapore|Spain 1
United States|Australia|Greece 1
United States|Australia|Greece|Poland|Sweden 1
United States|Australia|Hungary|Puerto Rico|Spain 1
United States|Australia|Israel|Norway 1
United States|Australia|Korea, Republic of 1
United States|Australia|Spain 1
United States|Australia|United Kingdom 1
United States|Austria|Belgium|Bulgaria|Canada|Czechia|France|Germany|Greece|Hungary|Israel|Italy|Netherlands|Poland|Romania|Russian Federation|Serbia|Spain|Sweden|United Kingdom 1
United States|Austria|Belgium|Czechia|Denmark|Estonia|France|Greece|Hungary|Israel|Italy|Korea, Republic of|Lithuania|Netherlands|Norway|Poland|Romania|Russian Federation|Spain|Taiwan|United Kingdom 1
United States|Austria|Belgium|France|Germany|Greece 1
United States|Austria|Canada|Czechia|Denmark|Germany|Greece|Israel|Italy|Norway|Portugal|Puerto Rico|Spain|Sweden|Switzerland 1
United States|Austria|Greece|Netherlands|Spain|Sweden 1
United States|Belgium 1
United States|Belgium|Brazil|Bulgaria|Canada|Czechia|France|Germany|Greece|Hungary|Netherlands|Poland|Portugal|Romania|Russian Federation|Slovakia|Spain|United Kingdom 1
United States|Belgium|Brazil|Canada|Denmark|France|Germany|Greece|Italy|Netherlands|Poland|Russian Federation|Spain 1
United States|Belgium|Canada|China|Greece|Korea, Republic of|Poland|Singapore|Spain|Sweden 1
United States|Belgium|Canada|Denmark|Germany|Italy|Spain|Sweden|United Kingdom 1
United States|Belgium|Canada|France|Germany|Greece|Spain|United Kingdom 1
United States|Belgium|Canada|France|Germany|Italy|Japan|Netherlands|Norway|Spain|Sweden 1
United States|Belgium|Canada|France|Germany|Italy|Japan|Spain 1
United States|Belgium|Denmark|Sweden 1
United States|Belgium|France|Germany|Israel|Netherlands|Spain 1
United States|Belgium|France|Greece|Italy|Poland 1
United States|Belgium|France|Italy|Spain 1
United States|Belgium|France|Netherlands|Spain|Sweden 1
United States|Belgium|France|Norway 1
United States|Belgium|Russian Federation 1
United States|Brazil|Canada|Czechia|France|Germany|Israel|Japan|Netherlands|Poland|Spain|Turkey|United Kingdom 1
United States|Brazil|Canada|France|Germany|Greece|Italy|Korea, Republic of|Mexico|Netherlands|Poland|Spain|Taiwan|Turkey|United Kingdom 1
United States|Brazil|Czechia|France|Germany|Israel|Japan|Spain|United Kingdom 1
United States|Canada|Czechia|Denmark|France|Germany|Greece|Italy|Spain 1
United States|Canada|Czechia|Spain|United Kingdom 1
United States|Canada|Denmark|Finland|Germany|Italy|Netherlands|Spain 1
United States|Canada|Denmark|Finland|Spain|United Kingdom 1
United States|Canada|France|Germany|Italy|Japan|Netherlands|Spain|United Kingdom 1
United States|Canada|France|Germany|Italy|Netherlands|Spain 1
United States|Canada|France|Italy|Poland 1
United States|Canada|France|Italy|Spain 1
United States|Canada|Germany 1
United States|Canada|Germany|Netherlands|Spain 1
United States|Canada|Germany|Spain 1
United States|Canada|Greece|Italy 1
United States|Canada|Israel|Italy|Russian Federation 1
United States|Canada|Italy 1
United States|Canada|Japan|Puerto Rico 1
United States|Canada|Spain 1
United States|Canada|United Kingdom 1
United States|China|France|Germany|Spain|United Kingdom 1
United States|Czech Republic|Germany 1
United States|Czechia|France 1
United States|Czechia|France|Greece|Netherlands|Poland 1
United States|Czechia|France|Spain 1
United States|Denmark|France|Netherlands|Spain|Sweden 1
United States|Denmark|France|Netherlands|United Kingdom 1
United States|Denmark|Italy|Netherlands|Sweden 1
United States|Denmark|Netherlands|Sweden 1
United States|Denmark|Norway|United Kingdom 1
United States|France|Australia|Austria|Belgium|Canada|Denmark|Germany|Ireland|Israel|Netherlands|Sweden|United Kingdom 1
United States|France|Germany 1
United States|France|Germany|Greece|Spain 1
United States|France|Germany|Spain|United Kingdom 1
United States|France|Italy|Netherlands|Spain|Switzerland 1
United States|France|Italy|Spain 1
United States|France|Korea, Republic of 1
United States|France|Netherlands 1
United States|France|Spain|United Kingdom 1
United States|Germany 1
United States|Germany|Italy|Spain 1
United States|Germany|Singapore|Spain 1
United States|Germany|Spain 1
United States|Germany|Spain|Sweden 1
United States|Greece|Italy|Poland 1
United States|Ireland|Puerto Rico 1
United States|Israel|Argentina|Australia|Austria|Belgium|Brazil|Canada|Chile|China|Colombia|Croatia|Czechia|Denmark|France|Germany|Greece|Hungary|Italy|Japan|Korea, Republic of|Mexico|Poland|Portugal|Russian Federation|Serbia|Singapore|South Africa|Spain|Sweden|Switzerland|Taiwan|Thailand|Turkey|United Kingdom 1
United States|Japan 1
United States|Netherlands 1
United States|Netherlands|Spain 1
United States|Peru|South Africa 1
United States|Philippines|United Kingdom 1
United States|Poland 1
United States|Puerto Rico|Saudi Arabia 1
United States|Puerto Rico|South Africa 1
United States|Singapore 1
United States|Spain 1
United States|Spain|United Kingdom 1
United States|Sweden 1

Sites per Study

Site_count Study_Count
1 823
2 121
3 70
4 55
5 68
6 41
7 37
8 41
9 40
10 36
11 28
12 20
13 22
14 17
15 7
16 13
17 11
18 9
19 12
20 10
21 7
22 8
23 5
24 8
25 2
26 6
27 4
28 6
29 1
30 7
31 6
32 4
33 3
34 4
35 4
36 2
37 3
38 3
39 3
40 5
41 1
42 2
43 2
44 1
45 1
46 2
47 1
48 1
49 4
54 2
55 2
56 1
57 2
58 1
59 2
60 1
61 1
63 2
64 3
68 4
69 2
70 1
71 1
73 2
74 2
76 1
77 3
78 1
79 1
80 2
82 1
84 1
86 2
91 2
92 1
93 1
94 1
95 1
98 1
99 1
105 1
107 2
109 1
110 1
111 2
112 1
114 1
115 1
117 1
121 1
127 1
128 1
138 1
140 2
141 1
145 1
147 1
148 1
157 1
163 1
165 2
178 1
198 1
210 1
213 1
215 1
224 1
235 1
241 1
248 1
278 1
288 1
309 1
326 1
336 1
393 1
417 1
485 1
504 1
505 1
506 1
507 1
613 1
920 1
1329 1

Phase

Phase Study_Count
Phase 2 663
Phase 1 400
Phase 1/Phase 2 233
Phase 3 221
N/A 112
Phase 4 25
Early Phase 1 18
Phase 2/Phase 3 13

Number of Arms

Number_of_Arms Count_of_Studies
1 826
2 399
3 102
4 46
5 25
6 13
7 8
8 4
9 2
10 3
11 5
12 2
13 2
17 1
21 1
37 1
NA 245

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 6.00000 2.0000 1.00000 3.00000 2.00000 4.0000 14.0000 18.000
1st Qu. 11.25000 20.0000 18.00000 30.00000 30.00000 22.0000 180.0000 48.750
Median 16.50000 50.0000 30.00000 50.00000 46.00000 86.0000 316.0000 111.500
Mean 21.27778 811.4037 44.65104 69.32589 88.27273 139.2308 417.2749 135.375
3rd Qu. 20.00000 100.0000 56.50000 80.00000 83.50000 169.0000 516.5000 164.750
Max. 100.00000 80761.0000 335.00000 449.00000 6452.00000 400.0000 4420.0000 500.000

Trial Group Type

group_type Group_Count
Experimental 2165
Active Comparator 291
NA 245
Other 96
Placebo Comparator 44
No Intervention 32
Sham Comparator 5

Intervention Model

intervention_model Study_Count
Single Group Assignment 989
Parallel Assignment 493
NA 113
Sequential Assignment 69
Crossover Assignment 16
Factorial Assignment 5

Primary Purpose

primary_purpose Study_Count
Treatment 1499
Supportive Care 84
Prevention 33
Diagnostic 23
Other 15
NA 14
Basic Science 7
Screening 5
Health Services Research 4
Device Feasibility 1

Observational Studies

Studies by Country

Country Study_Count
United States 70
NA 19
France 17
Italy 11
Korea, Republic of 8
Spain 8
Germany 7
Japan 7
Greece 4
United Kingdom 4
Denmark 3
Netherlands 3
Turkey 3
Austria 2
China 2
Norway 2
United States|Canada 2
Argentina|Brazil|Chile|Colombia|Guatemala|Mexico|Panama 1
Austria|Belgium|Czech Republic|France|Germany|Hungary|Italy|Poland|Romania|Spain|Switzerland|United Kingdom 1
Belgium 1
Belgium|Austria|Bulgaria|Czechia|France|Greece|Israel|Italy|Netherlands|Norway|Romania 1
Brazil 1
Canada 1
Czech Republic 1
Estonia|Spain|Algeria|Austria|Croatia|Denmark|France|Germany|Greece|Hungary|Israel|Latvia|Lithuania|Macedonia, The Former Yugoslav Republic of|Poland|Portugal|Russian Federation|Slovenia|South Africa|Turkey|Ukraine 1
Guadeloupe|Martinique 1
Italy|United Kingdom 1
Mexico 1
Russian Federation 1
Sweden 1
Switzerland 1
Taiwan 1
United States|Belgium|Brazil|China|Colombia|France|Germany|Greece|Israel|Italy|Mexico|Spain|Taiwan|Turkey|United Kingdom 1
United States|Belgium|France|Germany|Italy|Netherlands|Poland|Russian Federation|Spain|United Kingdom 1
United States|Canada|France|Germany|Italy|United Kingdom 1
United States|Canada|Spain 1
United States|Mexico|Saudi Arabia 1
United States|Puerto Rico 1

Sites per Study

Site_count Study_Count
1 120
2 10
3 4
4 1
5 2
6 4
7 2
8 1
9 4
10 3
13 2
15 1
16 1
20 6
21 1
22 1
23 1
24 1
25 1
27 2
28 1
29 1
30 1
35 1
38 1
39 1
40 1
44 2
65 1
69 1
73 1
81 1
94 1
112 1
120 1
126 1
137 2
138 1
144 1
161 1
207 1
253 1
453 1

Enrollment Metrics

Measure Observational
Min 7.000
1st Qu 60.500
Median 196.000
Mean 2105.749
3rd Qu 600.000
Max 99999.000

Observation Model

observational_model Study_Count
Cohort 92
Case-Only 55
Other 19
NA 11
Case-Control 8
Case Control 6
Family-Based 2

Time Perspective

time_perspective Study_Count
Prospective 144
Retrospective 27
NA 9
Cross-Sectional 6
Other 6
Longitudinal, Prospective 1

Registries

Studies by Country

Country Study_Count
United States 7
France 2
Algeria|Belgium|France|Lebanon 1
Argentina|Brazil|Colombia|Mexico|Panama 1
Austria|Belgium|Denmark|France|Germany|Ireland|Italy|Netherlands|Norway|Spain|Sweden|United Kingdom 1
Belgium|Denmark|Germany|Italy|Norway|Spain|Sweden|United Kingdom 1
China 1
Germany 1
Malaysia 1
NA 1
Portugal 1
Taiwan 1
United States|Puerto Rico 1

Sites per Study

Site_count Study_Count
1 11
2 1
4 1
7 1
12 1
20 1
33 1
75 1
118 1
135 1

Enrollment Metrics

Measure Registries
Min 100.00
1st Qu 425.00
Median 1150.00
Mean 51869.35
3rd Qu 2448.75
Max 999999.00

Registry Model

observational_model Study_Count
Cohort 15
Other 3
Case-Only 1
Ecologic or Community 1

Time Perspective

time_perspective Study_Count
Prospective 18
Cross-Sectional 1
Other 1

Follow-up

target_duration Study_Count
10 Years 5
5 Years 4
1 Year 2
2 Years 2
1 Day 1
24 Months 1
3 Years 1
30 Months 1
36 Months 1
8 Years 1
80 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03409692 Validation of a Personalised Medicine Tool for Multiple Myeloma That Predicts Treatment Effectiveness in Patients https://ClinicalTrials.gov/show/NCT03409692 Active, not recruiting University of Turin, Italy 2017-11-30
NCT03406091 Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients https://ClinicalTrials.gov/show/NCT03406091 Recruiting Fondazione Neoplasie Sangue Onlus 2020-02-28
NCT03405571 Validation of the 4TS RAM in the Prevention of Venous Thromboembolism in Patients With Plasma Cell Dyscrasias. https://ClinicalTrials.gov/show/NCT03405571 Recruiting University of Athens 2020-06-30
NCT03353545 Retrospective and Prospective Study of POmalidomide Plus LoW Dose Dexa Efficacy in RRMM Patients Under Real-Life Conditions https://ClinicalTrials.gov/show/NCT03353545 Completed Genesis Pharma S.A. 2020-02-21
NCT03323541 Use of Zarzio® in Post-autologous Stem Cell Transplantation Procedure https://ClinicalTrials.gov/show/NCT03323541 Completed University Hospital, Brest 2016-12-31
NCT03316209 Identification of Occupational Exposures in Acute Hematologic Malignancy https://ClinicalTrials.gov/show/NCT03316209 Recruiting Centre Hospitalier Intercommunal Creteil 2020-03-31
NCT03288974 Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea https://ClinicalTrials.gov/show/NCT03288974 Recruiting Celgene 2023-06-08
NCT03276481 Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation https://ClinicalTrials.gov/show/NCT03276481 Active, not recruiting Memorial Sloan Kettering Cancer Center 2020-08-28
NCT03210753 Study of Risk Factors and Genetic Association With Bortezomib-induced Peripheral Neuropathy in Multiple Myeloma https://ClinicalTrials.gov/show/NCT03210753 Recruiting National Taiwan University Hospital 2020-07-31
NCT03200626 Observational Study to Evaluate Hematopoietic Progenitor Cell Mobilization in Patients With Newly Diagnosed Multiple Myeloma https://ClinicalTrials.gov/show/NCT03200626 Active, not recruiting Medical College of Wisconsin 2021-09-24
NCT03190525 Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma https://ClinicalTrials.gov/show/NCT03190525 Active, not recruiting Gruppo Italiano Malattie EMatologiche dell’Adulto 2019-01-02
NCT03188536 Clinical and Sociodemographic Characterization of Multiple Myeloma Patients With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study) https://ClinicalTrials.gov/show/NCT03188536 Completed Takeda 2018-11-15
NCT03169361 NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) “Relapsed/Refractory Multiple Myeloma” https://ClinicalTrials.gov/show/NCT03169361 Active, not recruiting Takeda 2021-03-31
NCT03127761 Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma https://ClinicalTrials.gov/show/NCT03127761 Recruiting Center for International Blood and Marrow Transplant Research 2027-05-31
NCT03091127 Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe https://ClinicalTrials.gov/show/NCT03091127 Completed Amgen 2020-03-17
NCT03006315 Mobile Health Device Study for Myeloma Patients https://ClinicalTrials.gov/show/NCT03006315 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-06-30
NCT03001804 Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients https://ClinicalTrials.gov/show/NCT03001804 Recruiting Celgene 2021-12-30
NCT02997813 Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies https://ClinicalTrials.gov/show/NCT02997813 Completed Intergroupe Francophone du Myelome 2015-12-31
NCT02976493 Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma https://ClinicalTrials.gov/show/NCT02976493 Completed Bristol-Myers Squibb 2018-06-18
NCT02976272 Neurotoxic Effect of Bortezomib Treatment in Patient With Myeloma Multiple https://ClinicalTrials.gov/show/NCT02976272 Recruiting University Hospital, Clermont-Ferrand 2020-12-31
NCT02970747 Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone in Multiple Myeloma Patients https://ClinicalTrials.gov/show/NCT02970747 Active, not recruiting iOMEDICO AG 2022-12-23
NCT02946333 A Study to Assess Disease Burden, in Terms of Health-related Quality of Life and Direct Healthcare Costs, in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Autologous Stem Cell Transplant (ASCT) in Spain https://ClinicalTrials.gov/show/NCT02946333 Recruiting Celgene 2020-10-10
NCT02922543 A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use https://ClinicalTrials.gov/show/NCT02922543 Active, not recruiting Celgene 2020-06-19
NCT02921828 A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg https://ClinicalTrials.gov/show/NCT02921828 Active, not recruiting Celgene 2025-05-20
NCT02921802 A Study of Special Use Results Surveillance of Revlimid 5mg Capsules https://ClinicalTrials.gov/show/NCT02921802 Active, not recruiting Celgene 2020-06-19
NCT02918695 Comparison of Geriatric Screening Methods in Newly Diagnosed Multiple Myeloma Patients https://ClinicalTrials.gov/show/NCT02918695 Recruiting Universitaire Ziekenhuizen Leuven 2019-12-31
NCT02917239 Prevalence of Ocular Disorders in Multiple Myeloma (MM-OO-16) https://ClinicalTrials.gov/show/NCT02917239 Completed Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 2016-09-30
NCT02902900 An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice https://ClinicalTrials.gov/show/NCT02902900 Recruiting Celgene 2019-09-30
NCT02892383 Quality of Life the Danish Multiple Myeloma Patients https://ClinicalTrials.gov/show/NCT02892383 Recruiting Odense University Hospital 2022-09-01
NCT02885623 Role of CX3CR1-expressing Cells in Hematologic Malignancy https://ClinicalTrials.gov/show/NCT02885623 Recruiting Saint Vincent’s Hospital, Korea 2019-08-31
NCT02885038 Effect of Product Related Factors on Platelet Concentrate Transfusion Response in Patients With Hematologic Malignacies https://ClinicalTrials.gov/show/NCT02885038 Completed Etablissement Français du Sang 2016-03-31
NCT02884102 MMRF Molecular Profiling Protocol https://ClinicalTrials.gov/show/NCT02884102 Recruiting Multiple Myeloma Research Foundation 2023-06-30
NCT02861287 Economic Evaluation of the Use of Plerixafor for Autologous HSC Transplantation for Multiple Myeloma https://ClinicalTrials.gov/show/NCT02861287 Completed Institut Paoli-Calmettes 2015-12-31
NCT02840110 Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product https://ClinicalTrials.gov/show/NCT02840110 Enrolling by invitation Unum Therapeutics Inc. 2035-12-31
NCT02842229 A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms https://ClinicalTrials.gov/show/NCT02842229 Completed Celgene 2017-02-02
NCT02786511 Longterm Follow-up of Subjects Treated With bb2121 https://ClinicalTrials.gov/show/NCT02786511 Completed Celgene 2019-10-11
NCT02761187 An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants https://ClinicalTrials.gov/show/NCT02761187 Active, not recruiting Takeda 2024-07-01
NCT02741999 A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early https://ClinicalTrials.gov/show/NCT02741999 Completed Tufts Medical Center 2020-04-05
NCT02741544 Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM]) https://ClinicalTrials.gov/show/NCT02741544 Active, not recruiting Celgene 2021-08-21
NCT02726750 Prospective Observational Study of Clinical and Genomic Predictors of Progression to Myeloma in Asymptomatic Monoclonal Gammopathies https://ClinicalTrials.gov/show/NCT02726750 Recruiting M.D. Anderson Cancer Center 2021-12-31
NCT02671448 Pilot Trial of Homebound Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT02671448 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-01-31
NCT02627261 Multiple Myeloma Minimal Residual Disease https://ClinicalTrials.gov/show/NCT02627261 Recruiting Hospices Civils de Lyon 2022-05-31
NCT02608515 A Retrospective Chart Review Study of the Outcomes of 2nd Line Therapy With LEn/Dex in Greek Patients With R/R Multiple MyEloma and the Treatment PatterNs Following Progressive Disease https://ClinicalTrials.gov/show/NCT02608515 Completed Genesis Pharma S.A. 2016-09-30
NCT01676805 Tissue Collection for Studies of Lymph Cancer https://ClinicalTrials.gov/show/NCT01676805 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT01109407 Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM) https://ClinicalTrials.gov/show/NCT01109407 Completed National Institutes of Health Clinical Center (CC) NA
NCT01351545 A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) https://ClinicalTrials.gov/show/NCT01351545 Recruiting Center for International Blood and Marrow Transplant Research 2021-10-31
NCT00900198 Collection of Tissue Samples for Cancer Research https://ClinicalTrials.gov/show/NCT00900198 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT02559583 Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin’s Lymphoma (NHL) in Latin America https://ClinicalTrials.gov/show/NCT02559583 Completed Janssen-Cilag Ltd. 2016-06-30
NCT02555839 Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice https://ClinicalTrials.gov/show/NCT02555839 Recruiting Celgene 2022-09-30
NCT02556905 A Study to Collect and Evaluate the Safety and Efficacy Information of Korean Multiple Myeloma Patients Treated With REVLIMID®, After Approval of Marketing Authorization for New Drug in Korea https://ClinicalTrials.gov/show/NCT02556905 Completed Celgene 2016-11-30
NCT02537808 Non-interventional Study of Lenalidomide / Dexamethasone as First Line Therapy in Patients With Multiple Myeloma https://ClinicalTrials.gov/show/NCT02537808 Active, not recruiting iOMEDICO AG 2020-09-30
NCT02528838 An Observational Study to Assess Safety and Outcome of the Various Medication Usage Patterns in Clinical Routine Practice in Patients Receiving Lenalidomide. https://ClinicalTrials.gov/show/NCT02528838 Completed Celgene 2016-06-30
NCT02474563 Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma https://ClinicalTrials.gov/show/NCT02474563 Completed Janssen Korea, Ltd., Korea 2014-05-31
NCT02474160 Collection and Storage of Tissue and Blood Samples From Patients With Cancer https://ClinicalTrials.gov/show/NCT02474160 Recruiting National Cancer Institute (NCI) 2021-05-04
NCT02473757 Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies https://ClinicalTrials.gov/show/NCT02473757 Enrolling by invitation National Institutes of Health Clinical Center (CC) 2034-07-01
NCT02451592 Fungemia in Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02451592 Completed Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne 2015-12-31
NCT02439476 Non-interventional Study on Salvage Auto in Relapsed Myeloma https://ClinicalTrials.gov/show/NCT02439476 Active, not recruiting Association for Training, Education, and Research in Hematology, Immunology, and Transplantation 2020-06-08
NCT02434484 Symbenda Post-Marketing Surveillance (PMS) https://ClinicalTrials.gov/show/NCT02434484 Active, not recruiting Eisai Inc. 2020-04-30
NCT02403102 Imageguided Theranostics in Multiple Myeloma https://ClinicalTrials.gov/show/NCT02403102 Active, not recruiting Institute of Cancer Research, United Kingdom 2020-03-31
NCT02394210 Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma https://ClinicalTrials.gov/show/NCT02394210 Active, not recruiting Celgene 2021-01-31
NCT02387879 A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR https://ClinicalTrials.gov/show/NCT02387879 Active, not recruiting Celgene 2021-12-31
NCT02291965 Blood Samples to Identify Biomarkers of Busulfan https://ClinicalTrials.gov/show/NCT02291965 Active, not recruiting Fred Hutchinson Cancer Research Center 2019-04-20
NCT02294487 Study of the Immune Response After Vaccination in Multiple Myeloma Patients https://ClinicalTrials.gov/show/NCT02294487 Completed Aurora Health Care 2016-01-28
NCT02269592 Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome https://ClinicalTrials.gov/show/NCT02269592 Recruiting Dana-Farber Cancer Institute 2024-12-31
NCT02212262 Role of Osteocytes in Myeloma Bone Disease https://ClinicalTrials.gov/show/NCT02212262 Recruiting Indiana University 2019-06-30
NCT02187731 Functional Imaging in Multiple Myeloma -PET/CT and Diffusion Weighted Imaging in Multiple Myeloma https://ClinicalTrials.gov/show/NCT02187731 Active, not recruiting Odense University Hospital 2019-12-31
NCT02178579 Prospective Observation of Cardiac Safety With Proteasome Inhibition https://ClinicalTrials.gov/show/NCT02178579 Active, not recruiting Vanderbilt University Medical Center 2020-02-29
NCT02164071 Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies https://ClinicalTrials.gov/show/NCT02164071 Completed Celgene 2013-12-03
NCT02095379 Oligosecretary Myeloma: Prevalence and Its Clinical Significance https://ClinicalTrials.gov/show/NCT02095379 Completed Samsung Medical Center 2013-12-31
NCT02026505 Evaluation of Cardiotoxic Effects of Bortezomib https://ClinicalTrials.gov/show/NCT02026505 Completed Oregon Health and Science University 2016-12-31
NCT02075996 Non-interventional Study With Pomalidomide (Imnovid®) https://ClinicalTrials.gov/show/NCT02075996 Active, not recruiting iOMEDICO AG 2021-03-31
NCT02035189 Observational Study Evaluating the Potential Impact of Procalcitonin Testing on Care of Stemcell Transplant Recipients https://ClinicalTrials.gov/show/NCT02035189 Completed University of Arkansas 2014-09-30
NCT02033928 Comprehensive Frailty Assessment https://ClinicalTrials.gov/show/NCT02033928 Completed Ohio State University Comprehensive Cancer Center 2017-08-31
NCT01958528 Study Of Circulating Multiple Myeloma Cells As A Biomarker of MGUS And SMM https://ClinicalTrials.gov/show/NCT01958528 Active, not recruiting Abramson Cancer Center of the University of Pennsylvania 2019-01-11
NCT01931644 At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions https://ClinicalTrials.gov/show/NCT01931644 Recruiting Sanguine Biosciences 2025-08-31
NCT01880762 Evaluation of PET/MR and PET/CT Imaging for Bone Marrow Lesions https://ClinicalTrials.gov/show/NCT01880762 Completed NYU Langone Health 2016-07-31
NCT01855698 PENELOPE Observational Study: Prophylaxis and Treatment of Arterial and Venous Thromboembolism https://ClinicalTrials.gov/show/NCT01855698 Completed Gruppo Italiano Malattie EMatologiche dell’Adulto 2018-03-15
NCT01838512 Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE) https://ClinicalTrials.gov/show/NCT01838512 Recruiting Bristol-Myers Squibb 2024-06-13
NCT01820546 Cancer Stem Cells in Multiple Myeloma https://ClinicalTrials.gov/show/NCT01820546 Completed Ankara University 2016-01-31
NCT01804140 A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib) https://ClinicalTrials.gov/show/NCT01804140 Completed Genentech, Inc. 2013-09-30
NCT01746030 Geriatric Assessments in Senior Adults With Multiple Myeloma https://ClinicalTrials.gov/show/NCT01746030 Completed Washington University School of Medicine 2014-12-31
NCT01697839 Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients https://ClinicalTrials.gov/show/NCT01697839 Completed Oncotherapeutics 2015-08-31
NCT01675245 An Observational Study of Chinese Multiple Myeloma Patients Treated With Velcade https://ClinicalTrials.gov/show/NCT01675245 Completed Xian-Janssen Pharmaceutical Ltd. 2010-05-31
NCT01622582 Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple Myeloma https://ClinicalTrials.gov/show/NCT01622582 Completed University of Arkansas 2013-03-31
NCT01626547 Biosimilar Retacritâ„¢ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology https://ClinicalTrials.gov/show/NCT01626547 Completed Hospira, now a wholly owned subsidiary of Pfizer 2012-12-31
NCT01572857 Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple Myeloma https://ClinicalTrials.gov/show/NCT01572857 Completed Rennes University Hospital 2018-01-31
NCT01524445 Retrospective Survey of Re-treatment With Bortezomib https://ClinicalTrials.gov/show/NCT01524445 Completed Janssen Pharmaceutica N.V., Belgium NA
NCT01508416 Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma https://ClinicalTrials.gov/show/NCT01508416 Completed Centre Hospitalier Universitaire de Saint Etienne 2014-12-31
NCT01472627 Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro https://ClinicalTrials.gov/show/NCT01472627 Completed Dana-Farber Cancer Institute 2018-01-31
NCT01459653 Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor https://ClinicalTrials.gov/show/NCT01459653 Completed Sandoz 2013-08-31
NCT01454297 Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile https://ClinicalTrials.gov/show/NCT01454297 Active, not recruiting Multiple Myeloma Research Foundation 2023-09-30
NCT01440556 Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma https://ClinicalTrials.gov/show/NCT01440556 Completed Azienda Ospedaliera San Giovanni Battista 2013-01-31
NCT01430546 Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second Line https://ClinicalTrials.gov/show/NCT01430546 Completed Karolinska University Hospital 2016-01-31
NCT01410981 Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma https://ClinicalTrials.gov/show/NCT01410981 Completed Medical University of South Carolina 2014-06-30
NCT01402687 SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT) https://ClinicalTrials.gov/show/NCT01402687 Completed Dana-Farber Cancer Institute 2013-02-28
NCT01394640 Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Onco- Hematologic Patients https://ClinicalTrials.gov/show/NCT01394640 Completed Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 2010-05-31
NCT01374412 Investigation of Bone Defects and Microcirculation With Computed Tomography and Magnetic Resonance Imaging https://ClinicalTrials.gov/show/NCT01374412 Recruiting German Cancer Research Center 2019-07-31
NCT01362972 Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients Receiving Plerixafor https://ClinicalTrials.gov/show/NCT01362972 Completed Sanofi 2016-06-30
NCT04393090 eHealth for the Elderly https://ClinicalTrials.gov/show/NCT04393090 Completed Cankado Service GmbH 2017-05-31
NCT04328662 Ninlaro Intensive Drug Monitoring Protocol https://ClinicalTrials.gov/show/NCT04328662 Recruiting Takeda 2024-10-31
NCT04273425 Bone Pain in Multiple Myeloma- a Translational Study https://ClinicalTrials.gov/show/NCT04273425 Recruiting Sheffield Teaching Hospitals NHS Foundation Trust 2020-12-31
NCT04260490 Multiple Myeloma and Environmental Exposure to Pesticides in the French West Indies: A Population Based Case-control Study. https://ClinicalTrials.gov/show/NCT04260490 Recruiting Centre Hospitalier Universitaire de Pointe-a-Pitre 2022-11-30
NCT04242121 The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative Determination of the Circulating Plasma Cells in the Peripheral Blood https://ClinicalTrials.gov/show/NCT04242121 Recruiting St. Petersburg State Pavlov Medical University 2023-01-31
NCT04221178 Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission https://ClinicalTrials.gov/show/NCT04221178 Recruiting Memorial Sloan Kettering Cancer Center 2022-01-03
NCT04151615 VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma https://ClinicalTrials.gov/show/NCT04151615 Recruiting Boryung Pharmaceutical Co., Ltd 2022-09-30
NCT04135079 Immune Profiling in Multiple Myeloma https://ClinicalTrials.gov/show/NCT04135079 Recruiting University of Turin, Italy 2021-04-01
NCT04122092 Evaluation of Ultrasensitive Chromosomal Aneuploidy Detection for Detecting Minimal Residual Disease in Multiple Myeloma https://ClinicalTrials.gov/show/NCT04122092 Recruiting Shanghai Changzheng Hospital 2021-10-20
NCT04114084 Sleep Apnea in Patients With MGUS and MM https://ClinicalTrials.gov/show/NCT04114084 Recruiting University of Iowa 2024-05-23
NCT04045561 Development of a Standardized Reference Guide for Tuning Adherence to Dispense During a Initial Pharmaceutical Consulting (CP ) to the Patient With Multiple Myeloma Oral Chemotherapy Primocure https://ClinicalTrials.gov/show/NCT04045561 Completed Centre Hospitalier Universitaire de Nīmes 2016-12-31
NCT04035226 A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment https://ClinicalTrials.gov/show/NCT04035226 Recruiting Janssen-Cilag Ltd. 2022-04-28
NCT04004338 Carfilzomib in Combination for the Treatment of RR MM https://ClinicalTrials.gov/show/NCT04004338 Recruiting Black Sea Hematology Association 2021-04-14
NCT03983486 Rationale for Cytogenetic Risk Stratification by Imaging Flow Cytometry in Multiple Myeloma https://ClinicalTrials.gov/show/NCT03983486 Recruiting Centre Hospitalier Universitaire, Amiens 2020-11-30
NCT03966443 Fluciclovine PET/CT in Multiple Myeloma Patients https://ClinicalTrials.gov/show/NCT03966443 Recruiting Oslo University Hospital 2020-01-31
NCT03951220 The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone Loss https://ClinicalTrials.gov/show/NCT03951220 Recruiting Oxford University Hospitals NHS Trust 2020-12-30
NCT03890614 Novel 3D Myeloma Organoid to Study Disease Biology and Chemosensitivity https://ClinicalTrials.gov/show/NCT03890614 Recruiting Wake Forest University Health Sciences 2020-07-31
NCT03848676 Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma https://ClinicalTrials.gov/show/NCT03848676 Recruiting University of Turin, Italy 2023-07-01
NCT03777410 Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma https://ClinicalTrials.gov/show/NCT03777410 Recruiting Travera LLC 2021-01-31
NCT03779555 Lenalidomide Adherence in Older Adults https://ClinicalTrials.gov/show/NCT03779555 Recruiting Washington University School of Medicine 2020-09-30
NCT03702088 Place of the Hevylite Test in the Evaluation of MRD in Myeloma https://ClinicalTrials.gov/show/NCT03702088 Recruiting University Hospital, Montpellier 2020-12-01
NCT03689595 Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE) https://ClinicalTrials.gov/show/NCT03689595 Recruiting Dana-Farber Cancer Institute 2033-10-31
NCT03679351 “FU-IFM2009” Database Post IFM/DFCI 2009 Study https://ClinicalTrials.gov/show/NCT03679351 Recruiting University Hospital, Toulouse 2020-11-30
NCT03638232 Myeloma Treatment in Real Life https://ClinicalTrials.gov/show/NCT03638232 Completed University Hospital, Toulouse 2015-09-30
NCT03618212 MRI in Multiple Myeloma: Analysis of the Axial Skeleton Versus Whole Body. What is the Required Analysis? https://ClinicalTrials.gov/show/NCT03618212 Recruiting Centre Hospitalier Universitaire de Nīmes 2020-05-30
NCT03616483 Collection of Specimens and Clinical Data to Create A Bio-repository for Multiple Myeloma https://ClinicalTrials.gov/show/NCT03616483 Recruiting Indiana University 2023-06-30
NCT03602755 A Study of the First-line Treatment of Patients With Newly Diagnosed Transplant-ineligible Multiple Myeloma in Spain https://ClinicalTrials.gov/show/NCT03602755 Completed Celgene 2019-01-18
NCT03537222 Quality of Life in Patients With Multiple Myeloma-validation Study https://ClinicalTrials.gov/show/NCT03537222 Recruiting Zurich University of Applied Sciences 2020-10-31
NCT03506386 Multiple Myeloma (MM) Profile in Brazil: A Retrospective Observational Analysis https://ClinicalTrials.gov/show/NCT03506386 Completed Takeda 2019-11-08
NCT03493737 Cost-Utility Analysis Hospital Versus Home in Multiple Myeloma https://ClinicalTrials.gov/show/NCT03493737 Active, not recruiting Central Hospital, Nancy, France 2019-08-15
NCT03490084 Impacts on Health Outcomes and Resources Utilization of Hospital-at-home for Elderly Patients With Multiple Myeloma https://ClinicalTrials.gov/show/NCT03490084 Recruiting Assistance Publique - Hôpitaux de Paris 2022-10-31
NCT03477643 Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM) https://ClinicalTrials.gov/show/NCT03477643 Recruiting PETHEMA Foundation 2020-09-30
NCT03433365 Monitoring of Deep of Response During Lenalidomide Maintenance in MM Patients Achieving at Least Very Good Partial Response (MRD) https://ClinicalTrials.gov/show/NCT03433365 Completed Fondazione Neoplasie Sangue Onlus 2016-03-31
NCT03433001 A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone https://ClinicalTrials.gov/show/NCT03433001 Active, not recruiting Takeda 2021-05-31
NCT03421132 Multiple Myeloma Molecular Monitoring Study https://ClinicalTrials.gov/show/NCT03421132 Recruiting Horizon Health Network 2022-12-31
NCT01268774 Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide. https://ClinicalTrials.gov/show/NCT01268774 Completed LEO Pharma 2011-05-31
NCT01241396 A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure https://ClinicalTrials.gov/show/NCT01241396 Completed Janssen Pharmaceutica N.V., Belgium 2014-11-30
NCT01234129 Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma https://ClinicalTrials.gov/show/NCT01234129 Completed Instituto Mexicano del Seguro Social 2009-12-31
NCT01199562 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01199562 Completed City of Hope Medical Center 2013-12-31
NCT01177527 Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders https://ClinicalTrials.gov/show/NCT01177527 Active, not recruiting Dana-Farber Cancer Institute 2021-01-31
NCT01139476 Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study https://ClinicalTrials.gov/show/NCT01139476 Completed National Institutes of Health Clinical Center (CC) NA
NCT01141959 Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients https://ClinicalTrials.gov/show/NCT01141959 Completed Fred Hutchinson Cancer Research Center 2011-12-31
NCT01135849 B-Receptor Signaling in Cardiomyopathy https://ClinicalTrials.gov/show/NCT01135849 Completed Stanford University 2010-10-31
NCT01137825 Registry of Older Patients With Cancer https://ClinicalTrials.gov/show/NCT01137825 Active, not recruiting UNC Lineberger Comprehensive Cancer Center 2030-06-30
NCT01137643 Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer https://ClinicalTrials.gov/show/NCT01137643 Active, not recruiting UNC Lineberger Comprehensive Cancer Center 2040-07-31
NCT01132833 Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving Chemotherapy https://ClinicalTrials.gov/show/NCT01132833 Completed UNC Lineberger Comprehensive Cancer Center 2012-12-31
NCT01081028 Connect® MM- The Multiple Myeloma Disease Registry https://ClinicalTrials.gov/show/NCT01081028 Active, not recruiting Celgene 2024-12-31
NCT01079429 Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From MGUS and SMM. https://ClinicalTrials.gov/show/NCT01079429 Active, not recruiting Rennes University Hospital 2014-01-31
NCT01060202 Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib https://ClinicalTrials.gov/show/NCT01060202 Completed Janssen Korea, Ltd., Korea 2011-07-31
NCT01030302 A Retreatment Study With Bortezomib for Multiple Myeloma https://ClinicalTrials.gov/show/NCT01030302 Completed Janssen Korea, Ltd., Korea 2010-09-30
NCT01026701 Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients. https://ClinicalTrials.gov/show/NCT01026701 Completed Janssen Korea, Ltd., Korea 2009-11-30
NCT01021592 Quality of Life in Multiple Myeloma Patients Treated With Bortezomib https://ClinicalTrials.gov/show/NCT01021592 Completed Janssen Korea, Ltd., Korea 2008-07-31
NCT01006070 Health-Related Quality of Life (QOL), Physical and Respiratory Function in Patients With Myeloma Affecting the Spine https://ClinicalTrials.gov/show/NCT01006070 Completed University of California, San Francisco 2011-03-31
NCT01005628 Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS) https://ClinicalTrials.gov/show/NCT01005628 Completed Janssen Korea, Ltd., Korea 2012-03-31
NCT00993694 Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone https://ClinicalTrials.gov/show/NCT00993694 Completed Vanderbilt University Medical Center 2009-12-31
NCT00964821 Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00964821 Completed City of Hope Medical Center 2013-05-31
NCT00956033 Skin Biopsies in Chemotherapy-Induced Neuropathy https://ClinicalTrials.gov/show/NCT00956033 Completed Erasmus Medical Center 2012-02-29
NCT00919139 S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. https://ClinicalTrials.gov/show/NCT00919139 Completed Southwest Oncology Group 2010-11-30
NCT00910078 Serum Free Light Change in Multiple Myeloma https://ClinicalTrials.gov/show/NCT00910078 Completed Azienda Ospedaliera San Giovanni Battista NA
NCT00900263 S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma https://ClinicalTrials.gov/show/NCT00900263 Completed Southwest Oncology Group 2016-04-30
NCT00900406 Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00900406 Completed Vanderbilt-Ingram Cancer Center 2010-03-31
NCT00899080 Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide https://ClinicalTrials.gov/show/NCT00899080 Completed Eastern Cooperative Oncology Group 2008-08-04
NCT00898235 Collection of Samples and Clinical Data From Patients With Amyloid Diseases https://ClinicalTrials.gov/show/NCT00898235 Recruiting Boston Medical Center 2022-01-31
NCT00898066 S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood Disease https://ClinicalTrials.gov/show/NCT00898066 Completed Southwest Oncology Group 2007-06-30
NCT00898040 Study of DNA Samples From Patients With Multiple Myeloma https://ClinicalTrials.gov/show/NCT00898040 Completed Eastern Cooperative Oncology Group 2007-01-01
NCT00874211 S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases https://ClinicalTrials.gov/show/NCT00874211 Completed Southwest Oncology Group 2019-06-30
NCT04137523 Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression https://ClinicalTrials.gov/show/NCT04137523 Recruiting University of Turin, Italy 2019-08-12
NCT02849444 A Study to Assess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance https://ClinicalTrials.gov/show/NCT02849444 Active, not recruiting Celgene 2019-12-23
NCT03344328 Prevalence, Intensity and Consequences of Bortezomib-induced Neuropathic Disorders. https://ClinicalTrials.gov/show/NCT03344328 Recruiting University Hospital, Clermont-Ferrand 2019-12-31
NCT02767388 Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery https://ClinicalTrials.gov/show/NCT02767388 Completed University of Nebraska 2017-12-11
NCT02682667 Biospecimen Procurement for Experimental Transplantation and Immunology Branch Immunotherapy Protocols https://ClinicalTrials.gov/show/NCT02682667 Recruiting National Institutes of Health Clinical Center (CC) 2025-12-01
NCT01198457 Study to Investigate Adherence of Patients to Clodronate (Bonefos) Treatment https://ClinicalTrials.gov/show/NCT01198457 Completed Bayer 2010-06-30
NCT00911105 Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone https://ClinicalTrials.gov/show/NCT00911105 Completed iOMEDICO AG 2012-04-30
NCT00741780 Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662). https://ClinicalTrials.gov/show/NCT00741780 Completed Sanofi 2011-07-31
NCT00688168 Inflammatory Cytokines in Symptom Production in Multiple Myeloma https://ClinicalTrials.gov/show/NCT00688168 Completed M.D. Anderson Cancer Center 2019-01-08
NCT00639054 The Molecular Characterization of Multiple Myeloma at Relapse https://ClinicalTrials.gov/show/NCT00639054 Completed Rigshospitalet, Denmark 2014-12-31
NCT00626496 Family Study of Lymphoproliferative Disorders https://ClinicalTrials.gov/show/NCT00626496 Recruiting Mayo Clinic 2025-12-31
NCT00582621 Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders https://ClinicalTrials.gov/show/NCT00582621 Recruiting Memorial Sloan Kettering Cancer Center 2021-12-31
NCT00579917 Behavioral Intervention For BMT/SCT Survivors https://ClinicalTrials.gov/show/NCT00579917 Completed Memorial Sloan Kettering Cancer Center 2008-12-31
NCT00572338 Therapeutic Research in Multiple Myeloma https://ClinicalTrials.gov/show/NCT00572338 Completed University of Arkansas 2015-03-31
NCT00569842 Investigation of the Cylex® ImmuKnow® Assay https://ClinicalTrials.gov/show/NCT00569842 Completed Indiana University 2010-02-28
NCT00513175 Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia https://ClinicalTrials.gov/show/NCT00513175 Completed University of California, San Francisco NA
NCT00505999 Etiology of Multiple Myeloma: A Case-Control Study https://ClinicalTrials.gov/show/NCT00505999 Active, not recruiting M.D. Anderson Cancer Center 2020-07-31
NCT00476294 Long-Term Follow Up Study for AMD3100 Patients https://ClinicalTrials.gov/show/NCT00476294 Completed M.D. Anderson Cancer Center 2012-07-31
NCT00440635 Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma https://ClinicalTrials.gov/show/NCT00440635 Completed Janssen-Cilag International NV NA
NCT00440479 ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies. https://ClinicalTrials.gov/show/NCT00440479 Completed Janssen-Cilag B.V. 2011-01-31
NCT00427726 Follow-up of Breast Cancer and Multiple Myeloma Patients Previously Enrolled in NIH Gene Therapy Studies https://ClinicalTrials.gov/show/NCT00427726 Completed National Institutes of Health Clinical Center (CC) NA
NCT00339963 Genome Expression in Lymphoma, Leukemia and Multiple Myeloma https://ClinicalTrials.gov/show/NCT00339963 Completed National Institutes of Health Clinical Center (CC) NA
NCT00301275 Assessing Free Immunoglobulin Light Chains in Patients With Myeloma https://ClinicalTrials.gov/show/NCT00301275 Completed Royal Marsden NHS Foundation Trust NA
NCT00290095 Quality of Life in Patients With Multiple Myeloma https://ClinicalTrials.gov/show/NCT00290095 Completed Oslo University Hospital 2008-06-30
NCT00281814 Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant https://ClinicalTrials.gov/show/NCT00281814 Completed The Cleveland Clinic 2008-12-31
NCT00281801 Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation https://ClinicalTrials.gov/show/NCT00281801 Completed Case Comprehensive Cancer Center 2008-12-31
NCT00048958 Cytogenetic Studies in Acute Leukemia and Multiple Myeloma https://ClinicalTrials.gov/show/NCT00048958 Active, not recruiting Alliance for Clinical Trials in Oncology 2100-01-31
NCT00440765 VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands https://ClinicalTrials.gov/show/NCT00440765 Completed Janssen-Cilag B.V. 2012-01-31
NCT00352924 Agriculture Health Study https://ClinicalTrials.gov/show/NCT00352924 Active, not recruiting National Institutes of Health Clinical Center (CC) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT04458831 A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) https://ClinicalTrials.gov/show/NCT04458831 Recruiting Sanofi 2025-10-31
NCT03308474 Myeloma Registry Platform (MYRIAM) https://ClinicalTrials.gov/show/NCT03308474 Recruiting iOMEDICO AG 2026-12-31
NCT03106324 A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant https://ClinicalTrials.gov/show/NCT03106324 Recruiting Celgene 2025-03-31
NCT03234335 High Dose Therapy Followed by Autologous Transplantation for Myeloma Patients With Severe Renal Impairment https://ClinicalTrials.gov/show/NCT03234335 Recruiting Institut de Cancérologie de la Loire 2020-09-30
NCT02869555 Institut Paoli Calmettes Multiple Myeloma Database https://ClinicalTrials.gov/show/NCT02869555 Recruiting Institut Paoli-Calmettes 2030-01-31
NCT02692339 Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma https://ClinicalTrials.gov/show/NCT02692339 Recruiting Celgene 2023-09-29
NCT02298816 B-Cell Hematologic Malignancy Vaccination Registry https://ClinicalTrials.gov/show/NCT02298816 Enrolling by invitation Aurora Health Care 2024-12-31
NCT02164955 A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma. https://ClinicalTrials.gov/show/NCT02164955 Active, not recruiting Celgene 2022-08-31
NCT02012699 Integrated Cancer Repository for Cancer Research https://ClinicalTrials.gov/show/NCT02012699 Recruiting University of Nebraska 2099-12-31
NCT01890486 The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen https://ClinicalTrials.gov/show/NCT01890486 Recruiting Wake Forest University Health Sciences 2023-05-31
NCT01752075 A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan https://ClinicalTrials.gov/show/NCT01752075 Completed Celgene 2013-07-12
NCT01408225 Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource https://ClinicalTrials.gov/show/NCT01408225 Recruiting Ohio State University Comprehensive Cancer Center 2050-03-31
NCT04236063 Rehabilitation Needs of the Malaysian Haematological Cancer Survivors https://ClinicalTrials.gov/show/NCT04236063 Recruiting University of Malaya 2020-05-31
NCT04210791 Autologous Stem Cell Transplantation for Patients With AL Amyloidosis https://ClinicalTrials.gov/show/NCT04210791 Enrolling by invitation Nanjing University School of Medicine 2025-12-31
NCT04150289 A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat https://ClinicalTrials.gov/show/NCT04150289 Recruiting SecuraBio 2021-11-30
NCT04014764 Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy https://ClinicalTrials.gov/show/NCT04014764 Recruiting Notable Labs 2022-09-30
NCT03955900 A Registry Study of Participants With Multiple Myeloma in Latin America https://ClinicalTrials.gov/show/NCT03955900 Recruiting Janssen-Cilag Ltd. 2021-12-31
NCT03807128 MYeloma Resistance And Clonal Evolution https://ClinicalTrials.gov/show/NCT03807128 Recruiting Nantes University Hospital 2028-10-01
NCT03717844 Registry for Adults With Plasma Cell Disorders (PCD’s) https://ClinicalTrials.gov/show/NCT03717844 Recruiting UNC Lineberger Comprehensive Cancer Center 2028-02-29
NCT00889798 Tumor Registry of Lymphatic Neoplasia https://ClinicalTrials.gov/show/NCT00889798 Completed iOMEDICO AG 2019-08-31